immunomodulator raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Soon after the Big Bang, roughly 14 Gya (14 billion years ago), the only chemical elements present in the universe were hydrogen, helium, and lithium, the three lightest atoms in the periodic table. These elements gradually condensed into vast clouds of gas, which collapsed under gravity into rotating protostellar disks. Gravitational accretion of material at the hot and dense centers of these disks formed the first stars by the fusion of hydrogen. Early stars were massive and short-lived, producing all the heavier elements by stellar nucleosynthesis. Such element formation proceeds to its most stable element Iron-56. Heavier elements were formed during supernovas at the end of a star's lifecycle. Carbon, currently the fourth most abundant element in the universe, was formed mainly in white dwarf stars. As these stars reached the end of their lifecycles, they ejected heavier elements, including carbon and oxygen, throughout the universe. These allowed for the formation of rocky planets. According to the nebular hypothesis, the Solar System began to form 4.6 Gya with the gravitational collapse of part of a giant molecular cloud. Most of the collapsing mass collected in the center, forming the Sun, while the rest flattened into a protoplanetary disk out of which the planets formed.
Human chorionic gonadotropin is a glycoprotein composed of 237 amino acids with a molecular mass of 36.7 kDa, approximately 14.5kDa αhCG and 22.2kDa βhCG. It is heterodimeric, with an α (alpha) subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and a β (beta) subunit that is unique to hCG. The α (alpha) subunit is 92 amino acids long. The β-subunit of hCG gonadotropin (beta-hCG) contains 145 amino acids, encoded by six highly homologous genes that are arranged in tandem and inverted pairs on chromosome 19q13.3 - CGB (1, 2, 3, 5, 7, 8). It is known that CGB7 has a sequence slightly different from that of the others. The two subunits create a small hydrophobic core surrounded by a high surface area-to-volume ratio: 2.8 times that of a sphere. The vast majority of the outer amino acids are hydrophilic. beta-hCG is mostly similar to beta-LH, with the exception of a Carboxy Terminus Peptide (beta-CTP) containing four glycosylated serine residues that is responsible for hCG's longer half-life.
An – actinide Some actinides can exist in several oxide forms such as An2O3, AnO2, An2O5 and AnO3. For all actinides, oxides AnO3 are amphoteric and An2O3, AnO2 and An2O5 are basic, they easily react with water, forming bases:
Émile Zuckerkandl (July 4, 1922 – November 9, 2013) was an Austrian-born French biologist considered one of the founders of the field of molecular evolution. He introduced, with Linus Pauling, the concept of the "molecular clock", which enabled the neutral theory of molecular evolution.
The SAS raiding force, headed by Lieutenant-Colonel David Stirling, was discovered by an Italian reconnaissance unit, prompting Stirling to turn back to Kufra. The Rhodesians, meanwhile, were led into impassable country by a local guide, and swiftly retreated after being attacked by German bombers. Southern Rhodesian pilots played a part in the siege of Malta during 1942. John Plagis, a Rhodesian airman of Greek ancestry, joined the multinational group of Allied airmen defending the strategically important island in late March and on 1 April achieved four aerial victories in an afternoon, thereby becoming the siege's first Spitfire flying ace. By the time of his withdrawal in July he had been awarded the Distinguished Flying Cross twice. The British finally delivered vital supplies to Malta on 15 August with Operation Pedestal. Back in Salisbury, the Southern Rhodesian government was coming under pressure from Britain to put its armed forces under the purview of a regional command. Huggins decided in late October 1942 to join a unified Southern African Command headed by South Africa's Jan Smuts. This choice was motivated by a combination of strategic concerns and geopolitical manoeuvring. Apart from considering South Africa a more appropriate partner in geographical, logistical and cultural terms, Huggins feared that the alternative—joining the British East Africa Command—might detract from the autonomous nature of Southern Rhodesia's war effort, with possible constitutional implications. A shift in the deployment of the colony's troops duly occurred.
Sources: en.wikipedia.org
FGFR1 oncogene partner 2 (FGFR1OP2) is a protein that in humans is encoded by the gene FGFR1OP2. It was identified in a study on myeloproliferative syndrome (EMS). The study aimed to identify the partner genes to the fibroblast growth factor receptor 1 (FGFR1) involved in the syndrome. Using the 5'-RACE PCR technique, FGFR1OP2 was identified as a novel gene with no known function.
==== Member of the Royal Victorian Order (MVO) ==== Christian Mary Bailey, Curator to The Prince of Wales. Frederick Booth, Chief Heraldic Painter, College of Arms. Ann Teresa Brown, , lately British Overseas Trade Board. Matthew Nicholas Butler, lately Assistant Private Secretary to The Prince of Wales Pamela Margaret Clark, Deputy Registrar, Royal Archives, Windsor Castle. Claire Elizabeth Hunter-Craig, Secretary, Household of The Duke of Edinburgh. Reginald Elliott, Higher Executive Officer, Crown Estate, Windsor. Valerie Winifred Hampton, Personal Secretary to Princess Alexandra, the Honourable Lady Ogilvy. Chief Yeoman Warder Norman William Jackson, HM Tower of London. Alexander Masson, Head Gamekeeper, Balmoral Estate. John Ronald Pepper, lately of Collingwood & Company Limited. Inspector Stephen Lionel Robinson, Royalty and Diplomatic Protection Department, Metropolitan Police. Eileen Margaret Sly, lately the Westminster Abbey Trust. William Albert Stewart, Head Warden, Palace of Holyroodhouse. Prudence Sarah Sutcliffe, Assistant Curator of the Print Room, Windsor Castle. Lieutenant Colonel Patrick John Tabor, lately Equerry to The Prince of Wales.
The association of anti-tobacco smoking research and public health measures with the Nazi leadership may have contributed to the lack of attention paid to these studies. They were also published in German and Dutch. These studies were widely ignored. In 1947 the British Medical Council held a conference to discuss the reason for the rise in lung cancer deaths; unaware of the German studies, they planned and started their own. Five case-control studies published in 1950 by researchers from the US and UK did draw widespread attention. The strongest results were found by "Smoking and carcinoma of the lung. Preliminary report", by Richard Doll and Austin Bradford Hill, and the 1950 Wynder and Graham Study, entitled "Tobacco Smoking as a Possible Etiologic Factor in Bronchiogenic Carcinoma: A Study of Six Hundred and Eighty-Four Proved Cases". These two studies were the largest, and the only ones to carefully exclude ex-smokers from their non-smokers group. The other three studies also reported that, to quote one, "smoking was powerfully implicated in the causation of lung cancer". The Doll and Hill paper reported that "heavy smokers were fifty times as likely as non-smokers to contract lung cancer".
== Structure == ATP consists of three parts: a sugar, an amine base, and a phosphate group. More specifically, ATP consists of an adenine attached by the #9-nitrogen atom to the 1′ carbon atom of a sugar (ribose), which in turn is attached at the 5' carbon atom of the sugar to a triphosphate group. In its many reactions related to metabolism, the adenine and sugar groups remain unchanged, but the triphosphate is converted to di- and monophosphate, giving respectively the derivatives ADP and AMP. The three phosphoryl groups are labeled as alpha (α), beta (β), and, for the terminal phosphate, gamma (γ). In neutral solution, ionized ATP exists mostly as ATP4−, with a small proportion of ATP3−.
Primary sources below are listed at the head of each column, information sourced elsewhere is referenced directly in the relevant cells. Data is for models as marketed in the Japanese domestic market.
Sources: en.wikipedia.org
In contrast to other mechanical disruption methods the Microfluidizer breaks the cell membranes efficiently but gently, resulting in relatively large cell wall fragments (450 nm), and thus making it easier to separate the cell contents. This can lead to shorter filtration times and better centrifugation separation. Microfluidizer technology scales from one milliliter to thousands of liters.
== External links == An Extremely Detailed Map of the 2024 Election from The New York Times "Misinformation Dashboard: Election 2024. A tool tracking the topics and tactics of 2024 election misinformation". News Literacy Project. 2024. Retrieved September 30, 2024. Dovere, Edward-Isaac (November 6, 2024). "Where Harris' campaign went wrong". CNN. Retrieved November 7, 2024. "The Choice 2024: Harris vs. Trump". Frontline. Season 43. Episode 2. September 24, 2024. PBS. WGBH. Retrieved November 28, 2024. "The VP Choice: Vance vs. Walz". Frontline. Season 43. Episode 3. October 8, 2024. PBS. WGBH. Retrieved November 28, 2024.
=== EC 1.21.99 With unknown physiological acceptors === EC 1.21.99.1 EC 1.21.99.1: β-cyclopiazonate dehydrogenase EC 1.21.99.2: Now classified as EC 1.21.98.1, cyclic dehypoxanthinyl futalosine synthase. EC 1.21.99.3: thyroxine 5-deiodinase EC 1.21.99.4: thyroxine 5′-deiodinase EC 1.21.99.5: tetrachloroethene reductive dehalogenase
== Spectrum of activity == Tylosin has a wide spectrum of activity against Gram-positive bacteria including Staphylococcus, Streptococcus, Corynebacterium, and Erysipelothrix. It has a much narrower Gram-negative spectrum of activity, but has been shown to be active against Campylobacter coli, and certain spirochaetes. It has also been shown to be extremely active against Mycoplasma species isolated from both mammalian and avian hosts. The following represents MIC susceptibility data for a few medically significant pathogens:
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.